237 related articles for article (PubMed ID: 27507871)
1. Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
A'Hern RP
J Clin Oncol; 2016 Oct; 34(28):3474-6. PubMed ID: 27507871
[No Abstract] [Full Text] [Related]
2. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
3. N-of-1 trials in oncology.
Collette L; Tombal B
Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
[No Abstract] [Full Text] [Related]
4. Perils of the Pathologic Complete Response.
Rose BS; Winer EP; Mamon HJ
J Clin Oncol; 2016 Nov; 34(33):3959-3962. PubMed ID: 27551115
[No Abstract] [Full Text] [Related]
5. Pathology is a necessary and informative tool in oncology clinical trials.
Nagtegaal ID; West NP; van Krieken JH; Quirke P
J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
[TBL] [Abstract][Full Text] [Related]
6. Cancer concepts and principles: primer for the interventional oncologist-part I.
Hickey R; Vouche M; Sze DY; Hohlastos E; Collins J; Schirmang T; Memon K; Ryu RK; Sato K; Chen R; Gupta R; Resnick S; Carr J; Chrisman HB; Nemcek AA; Vogelzang RL; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1157-64. PubMed ID: 23809510
[TBL] [Abstract][Full Text] [Related]
7. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
Saad ED; Buyse M
J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
[No Abstract] [Full Text] [Related]
8. Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.
Sun Y; Wu W; Sargent D
Stat Med; 2016 Sep; 35(22):3923-32. PubMed ID: 27089832
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.
Markman M
Curr Oncol Rep; 2009 Jan; 11(1):1-2. PubMed ID: 19080733
[No Abstract] [Full Text] [Related]
10. The role of nonrandomized trials in the evaluation of oncology drugs.
Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
[TBL] [Abstract][Full Text] [Related]
11. Design considerations in clinical trials with cure rate survival data: A case study in oncology.
Sun S; Liu G; Lyu T; Xue F; Yeh TM; Rao S
Pharm Stat; 2018 Mar; 17(2):94-104. PubMed ID: 29159922
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MK; Sydes MR; Tannock IF; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e43-52. PubMed ID: 25638556
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
Robinson AG; Booth CM; Eisenhauer EA
Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
15. The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.
Markman M
J Cancer Res Clin Oncol; 1996; 122(10):573-4. PubMed ID: 8879253
[No Abstract] [Full Text] [Related]
16. CT2--the clinical trials control tower: overcoming barriers to opening oncology clinical trials.
Hammond AL; Waller EK; Finkelstein LB
J Clin Oncol; 2007 Apr; 25(10):1288; author reply 1288. PubMed ID: 17401022
[No Abstract] [Full Text] [Related]
17. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
18. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of geriatric principles in oncology clinical trials.
Hurria A
J Clin Oncol; 2007 Dec; 25(34):5350-1. PubMed ID: 18048814
[No Abstract] [Full Text] [Related]
20. Clinical Trials, End Points, and Statistics-Measuring and Comparing Cancer Treatments in Practice.
West H; Dahlberg S
JAMA Oncol; 2018 Dec; 4(12):1798. PubMed ID: 30193254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
